<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00190528</url>
  </required_header>
  <id_info>
    <org_study_id>JCOG0102</org_study_id>
    <secondary_id>C000000194</secondary_id>
    <nct_id>NCT00190528</nct_id>
  </id_info>
  <brief_title>A Trial of Neoadjuvant Chemotherapy + Surgery vs. Surgery for Bulky Stage I/II Cervical Cancer</brief_title>
  <official_title>Phase III Trial of Neoadjuvant Chemotherapy Followed by Surgery Versus Surgery Alone for Bulky Stage I/II Cervical Cancer: Japan Clinical Oncology Group Trial (JCOG0102)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Haruhiko Fukuda</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Ministry of Health, Labour and Welfare, Japan</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Japan Clinical Oncology Group</source>
  <brief_summary>
    <textblock>
      To investigate the clinical benefits of neoadjuvant chemotherapy for bulky stage I/II
      cervical cancer
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      We designed this randomized study to investigate the clinical benefits of neoadjuvant
      chemotherapy for bulky stage I/II cervical cancer. Patients with FIGO stage I/II with bulky
      disease are randomized to either neoadjuvant chemotherapy (BOMP: Cisplatin 14mg/m2 day 1-5,
      Bleomycin 7mg day 1-5, Mitomycin 7mg/m2 day 5, and Vincristine 0.7mg/m2 day every 21 days for
      2-4 cycles followed by radical hysterectomy or radical hysterectomy alone. The primary
      endpoint is overall survival and the secondary endpoints are progression-free survival,
      complication of surgery, completeness of radical hysterectomy, omission of postsurgical
      irradiation, completeness of postsurgical irradiation, response rate, and adverse events. A
      total 200 patients (100 per treatment arm) planned to accrue for this study within 5.5 years.
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>February 2002</start_date>
  <completion_date type="Actual">February 2009</completion_date>
  <primary_completion_date type="Actual">December 2004</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Diagnostic</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>overall survival</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>progression-free survival</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>complication of surgery</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>completeness of radical hysterectomy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>omission of postsurgical irradiation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>completeness of postsurgical irradiation</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>response rate</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>adverse events</measure>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">200</enrollment>
  <condition>Cervical Neoplasms</condition>
  <arm_group>
    <arm_group_label>Surgery</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Chemotherapy + Surgery</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>neoadjuvant chemotherapy + radical hysterectomy</intervention_name>
    <arm_group_label>Chemotherapy + Surgery</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>radical hysterectomy</intervention_name>
    <arm_group_label>Surgery</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Untreated cervical cancer

          2. Pathologically diagnosed squamous carcinoma

          3. FIGO stage Ib2, IIa (&gt;4cm), and IIb

          4. Measurable lesions

          5. Possible to radical hysterectomy

          6. Age: 20 to 70 years

          7. PS: 0 and 1

          8. WBC &gt; 3,000/mm3, Hb &gt; 9.0g/dl, Platelet &gt; 100,000 /mm3, SGOT/SGPT &lt; 60 IU/L, T-Bil &lt;
             1.5 mg/dL, Cr &lt; 1.2 mg/dL, PaO2 &gt; 80 torr, normal ECG

          9. Written informed consent

        Exclusion Criteria:

          1. Patients who have any evidence of the other cancer present within the last 5 years
             with the exception of carcinoma in situ or intramucosal cancer those are curable with
             local therapy

          2. Women during pregnancy or breast-feeding

          3. Patients with psychiatric illness

          4. Patients who have active infection

          5. Patients who have uncontrolled diabetes or uncontrolled hypertension

          6. Patients who have positive HBs

          7. Patients who have had heart failure, unstable angina, or myocardial infarction within
             the past 6 months

          8. Patients with interstitial pneumonitis or pulmonary fibrosis

          9. Patients who are unable to undergo radical hysterectomy for complication of excessive
             obesity, liver cirrhosis, or bleeding tendency
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toshiharu Kamura, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Kurume University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Center Hospital</name>
      <address>
        <city>Chuo-ku</city>
        <state>Tokyo</state>
        <zip>1040045</zip>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
  </location_countries>
  <link>
    <url>http://www.jcog.jp/</url>
  </link>
  <verification_date>September 2016</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 13, 2005</study_first_submitted>
  <study_first_submitted_qc>September 13, 2005</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 19, 2005</study_first_posted>
  <last_update_submitted>September 20, 2016</last_update_submitted>
  <last_update_submitted_qc>September 20, 2016</last_update_submitted_qc>
  <last_update_posted type="Estimate">September 22, 2016</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Japan Clinical Oncology Group</investigator_affiliation>
    <investigator_full_name>Haruhiko Fukuda</investigator_full_name>
    <investigator_title>JCOG Data Center</investigator_title>
  </responsible_party>
  <keyword>cervical cancer</keyword>
  <keyword>drug therapy</keyword>
  <keyword>cisplatin</keyword>
  <keyword>bleomycin</keyword>
  <keyword>mitomycin</keyword>
  <keyword>vincristine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Uterine Cervical Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

